EPO squeezes hESC patenting in line with EU court ruling, but impact could be limited
This article was originally published in SRA
Executive Summary
The European Patent Office has declared that a stem cell invention derived using a method that necessarily involves the destruction of a human embryo cannot be patented1,2. In doing so, it has followed last year's ruling from the Court of Justice of the EU, even though as a non-EU body it was not bound to do so.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.